Operates a diversified agri-business spanning animal feed, oil palm plantations, crop protection, dairy and poultry processing. Animal Nutrition is the largest segment at INR 4,941.54 crore in FY26, selling cattle, poultry and aquaculture feed to livestock farmers. Vegetable Oil, built on oil palm plantations and milling, generated INR 1,997.76 crore with the highest segment EBIT of INR 386.05 crore; a new integrated oil palm complex has been inaugurated at Khammam, Telangana with INR 300 crore cumulative investment, targeting plantation area growth from 10,000 ha to 30,000 ha by 2030. Crop Care (INR 1,188.31 crore) includes Astec LifeSciences, where the CDMO contract-manufacturing mix reached 52% of revenue in FY26. Dairy (INR 1,589.02 crore) is run through Creamline Dairy, with profitability under pressure from elevated milk procurement costs. Poultry and processed food (INR 768.13 crore) sells live birds and branded items like Yummiez, with live bird trading being phased out over 4-5 years. Materials are the largest cost at 70.8% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Animal Nutrition (46%), Vegetable Oil (19%), Dairy (15%), Crop Care Business (11%), Poultry and processed food (7%), Others (2%). Diversified, asset-heavy agri-business spanning plantation, feed milling, dairy processing and contract manufacturing across five core segments.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 8,306 | 9,374 | 9,561 | 9,383 | 10,233 |
| EBITDA (ex other income) | 648 | 523 | 701 | 816 | 833 |
| margin % | 7.8 | 5.6 | 7.3 | 8.7 | 8.1 |
| Owners' profit | 403 | 302 | 360 | 430 | 445 |
| EPS, as reported (₹) | 20.96 | 15.71 | 18.71 | 22.35 | 24.58 |
| ROE % · ROCE % | 15.6 · 18.8 | 10.8 · 14.3 | 12.3 · 15.1 | 15.5 · 19.1 | 20.6 · 21.9 |
| Debt / equity (x) | 0.58 | 0.48 | 0.45 | 0.49 | 0.68 |
| Cash from operations | (120) | 874 | 678 | 969 | 1,281 |
| Capex | (271) | (359) | (384) | (225) | (297) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,449 | 2,450 | 2,134 | 2,614 | 2,567 | 2,718 | 2,333 | 2,855 |
| Profit before tax | 138 | 138 | 74 | 188 | 125 | 139 | 120 | 169 |
| Net profit | 96 | 110 | 66 | 149 | 84 | 110 | 102 | 128 |
| EPS (₹) | 5.84 | 5.80 | 3.68 | 8.35 | 4.81 | 5.97 | 5.45 | 6.99 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Animal Nutrition | 1,270 | 11.9 |
| Vegetable Oil | 1,998 | 18.8 |
| Crop Care Business | 313 | 2.9 |
| Dairy | 1,589 | 14.9 |
| Poultry and processed food | 581 | 5.5 |
| Others | 157 | 1.5 |
| Animal Feed | 3,672 | 34.5 |
| Crop Protection Business | 875 | 8.2 |
| Poultry and Processed Food | 187 | 1.8 |
| Total, before eliminations | 10,642 | 100.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Godrej Agrovet appoints new Chief Human Resources Officer | management changes | medium | — | — |
| 2 Sept 2026 · Godrej Agrovet replies to NSE volume query; confirms no undisclosed info | compliance | low | — | — |
| 1 Sept 2026 · Godrej Agrovet schedules analyst meetings from Sep 8 to 18, 2026 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godrej Agrovet schedules analyst and investor meetings from Sept 8 to 18 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godrej Agrovet to hold analyst and investor meetings from Sept 8 to 18 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godrej Agrovet schedules analyst and investor meetings in September 2026 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godrej Agrovet schedules 6 analyst and investor meetings from Sep 8 to 18, 2026 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godrej Agrovet schedules analyst/investor meetings from Sept 8-18, 2026 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godrej Agrovet schedules analyst and investor meetings from Sept 8 to 18, 2026 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godrej Agrovet schedules six analyst meetings from Sept 8 to 18, 2026 | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows |
|---|
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| GODREJ AGROVET LIMITED ◆ | 12,984 | 29.1 | 6.00 | 15.1 | 20.6 | 17.6 | 10.3 | 8.9 |
| AVANTI FEEDS LIMITED | 10,900 | 20.5 | 2.94 | 11.5 | 17.7 | 23.5 | 8.1 | 9.0 |
| MUKKA PROTEINS LIMITED | 984 | 14.2 | 1.86 | 12.1 | 10.8 | 12.8 | — | 10.1 |
| KSE LTD. | 569 | 0.8 | 1.63 | — | 24.0 | 30.5 | — | (0.5) |
| SHIVAM CHEMICALS LIMITED | 203 | 24.4 | — | — | — | 17.8 | — | — |
| AJOONI BIOTECH LIMITED | 60 | 14.5 | 0.66 | — | 4.7 | 6.2 | — | 3.1 |
| Mayank Cattle Food Limited | 57 | 7.5 | — | — | — | — | — | — |
| NARMADA AGROBASE LIMITED | 55 | 72.0 | — | — | — | — | — | 5.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 29.1 | 17.5 | 7 of 8 | 14% |
| P/B | 6.0 | 1.9 | 5 of 5 | 0% |
| ROCE | 17.6 | 17.7 | 4 of 6 | 40% |
| ROE | 20.6 | 17.7 | 2 of 5 | 75% |
| Debt / Equity | 0.7 | 0.2 | 4 of 5 | 25% |
| EBITDA margin | 8.9 | 7.2 | 3 of 6 | 60% |
| Revenue growth | 9.2 | 51.8 | 5 of 6 | 20% |
| Profit growth | (13.8) | (37.4) | 2 of 5 | 75% |
| Market cap | 12984 | 386 | 1 of 8 | 100% |
| Why |
|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
